In its 2015 re-evaluation of dodecyl gallate (E312), the EFSA ANS Panel concluded the available database was too limited to establish an ADI or apply a margin-of-safety approach, could not reach a definitive conclusion on the presence or absence of a carcinogenic potential, and was unable to identify any NOAEL; an adequate safety assessment would require a fuller toxicological database.
EFSA could not confirm that dodecyl gallate is safe: the data were too limited to set a safe daily limit, identify a no-effect level, or rule a cancer risk in or out. A proper assessment would need more toxicology studies.